Prostanoid receptors: Subtypes and signaling

被引:801
作者
Breyer, RM
Bagdassarian, CK
Myers, SA
Breyer, MD
机构
[1] Vanderbilt Univ, Div Nephrol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA
[4] Coll William & Mary, Dept Chem, Williamsburg, VA 23187 USA
[5] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA
[6] Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA
关键词
prostaglandin; GPCR; G protein; mutagenesis; alternative splicing;
D O I
10.1146/annurev.pharmtox.41.1.661
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cyclooxygenases metabolize arachidonate to five primary prostanoids: PGE(2), PGF(2 alpha), PGI(2), TxA(2), and PGD(2). These autacrine lipid mediators interact with specific members of a family of distinct G-protein-coupled prostanoid receptors, designated EP, FP, IP, TP, and DP, respectively. Each of these receptors has been cloned, expressed, and characterized. This family of eight prostanoid receptor complementary DNAs encodes seven transmembrane proteins which are typical of G-protein-coupled receptors and these receptors are distinguished by their ligand-binding profiles and the signal transduction pathways activated on ligand binding. Ligand-binding selectivity of these receptors is determined by both the transmembrane sequences and amino acid residues in the putative extracellular-loop regions. The selectivity of interaction between the receptors and G proteins appears to be mediated at least in part by the C-terminal tail region. Each of the EP1, EP3, FP, and TP receptors has alternative splice variants described that alter the coding sequence in the C-terminal intracellular tail region. The C-terminal variants modulate signal transduction, phosphorylation, and desensitization of these receptors, as well as altering agonist-independent constitutive activity.
引用
收藏
页码:661 / 690
页数:30
相关论文
共 156 条
[31]   STIMULATION OF RENIN RELEASE BY PGE2 AND PGI2 INFUSION IN THE DOG - ENHANCING EFFECT OF URETERAL OCCLUSION OR ADMINISTRATION OF ETHACRYNIC-ACID [J].
BUGGE, JF ;
STOKKE, ES ;
VIKSE, A ;
KIIL, F .
ACTA PHYSIOLOGICA SCANDINAVICA, 1990, 138 (02) :193-201
[32]   ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE BY THE HUMAN PROSTAGLANDIN EP(3A) RECEPTOR [J].
BURKEY, TH ;
REGAN, JW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 211 (01) :152-158
[33]   Increased renal formation of thromboxane A(2) and prostaglandin F-2 alpha in heart failure [J].
Castellani, S ;
Paladini, B ;
Paniccia, R ;
DiSerio, C ;
Vallotti, B ;
Ungar, A ;
Fumagalli, S ;
Cantini, C ;
Poggesi, L ;
Serneri, GGN .
AMERICAN HEART JOURNAL, 1997, 133 (01) :94-100
[34]   Functional interaction of the carboxylic acid group of agonists and the arginine residue of the seventh transmembrane domain of prostaglandin E receptor EP3 subtype [J].
Chang, CS ;
Negishi, M ;
Nishigaki, N ;
Ichikawa, A .
BIOCHEMICAL JOURNAL, 1997, 322 :597-601
[35]   The role of N-glycosylation of human thromboxane A2 receptor in ligand binding [J].
Chiang, N ;
Tai, HH .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1998, 352 (02) :207-213
[36]   A NOVEL INHIBITORY PROSTANOID RECEPTOR IN PIGLET SAPHENOUS-VEIN [J].
COLEMAN, RA ;
GRIX, SP ;
HEAD, SA ;
LOUTTIT, JB ;
MALLETT, A ;
SHELDRICK, RLG .
PROSTAGLANDINS, 1994, 47 (02) :151-168
[37]  
COLEMAN RA, 1994, PHARMACOL REV, V46, P205
[38]  
COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643
[39]   Dimerization of the delta opioid receptor: Implication for a role in receptor internalization [J].
Cvejic, S ;
Devi, LA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (43) :26959-26964
[40]   Mutagenic analysis of platelet thromboxane receptor cysteines - Roles in ligand binding and receptor-effector coupling [J].
DAngelo, DD ;
Eubank, JJ ;
Davis, MG ;
Dorn, GW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (11) :6233-6240